Stan Rose is a Ph.D. biologist, seasoned biotechnology executive, and serial entrepreneur. He has spent more than three decades working with leading scientists and clinicians to create substantial commercial value from inventions based on genome technology. Stan is President of Rose Ventures, a firm focused on consulting, directing, and investing in the life sciences, and currently serves as a Director for Xeno Biosciences, SerumDPT Inc., and Invenra. Highlights from earlier in his career include leading the polymerase chain reaction (PCR) business at Perkin Elmer through its acquisition by Hoffman LaRoche in 1991; co-founding Genetic MicroSystems, a microarray instrumentation company that was sold to Affymetrix in 2000; and serving as CEO of NimbleGen Systems, Inc., in the years leading up to the acquisition of the company by Roche in 2007. Most recently he was co-founder, Director, and CEO of Transplant Genomics, a molecular diagnostic services company commercializing tests to improve outcomes for organ transplant recipients, acquired by Eurofins in 2019. Stan received his BA from Cornell University and his PhD from the Massachusetts Institute of Technology.
